This results in a surge in GSDMC, promoting the growth of tumor cells and fostering tumorigenesis, positioning GSDMC as a potential therapeutic target for TGFβR2 mutant CRC (57). The gene discussed is TGFBR2; the disease is colorectal carcinoma.